Navigation Links
Boston Scientific Acquires Intelect Medical
Date:1/5/2011

is a progressive neurodegenerative disorder that affects 7 to 10 million people worldwide, according to the World Health Organization.

"The acquisition of Intelect Medical supports our long-term strategy of enhancing our product portfolio and gaining market share in the Neuromodulation space, and it will help us to provide the most advanced deep brain stimulation technology solutions for neurologists, neurosurgeons and their patients," said Michael Onuscheck, Senior Vice President and President, Neuromodulation for Boston Scientific.  "The GUIDE DBS system promises to be a major advance in deep brain stimulation therapy, especially when used in conjunction with our Vercise DBS System."

"This acquisition represents additional progress in our strategy to realign Boston Scientific's portfolio through the execution of our Priority Growth Initiatives," said Ray Elliott, President and Chief Executive Officer of Boston Scientific.  "Deep brain stimulation has enormous potential, and it is an important part of our Neuromodulation business growth plans.  We will continue to pursue additional Priority Growth Initiatives to strengthen our Company by buying or building products we understand, to be sold through sales forces we already have."

The Vercise DBS System is an investigational device and is limited by applicable law to investigational use only and is not available for sale.

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forw
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinsons Disease
2. Boston College physics professor Willie Padilla receives PECASE award
3. Stryker Announces Definitive Agreement to Acquire the Neurovascular Division of Boston Scientific for $1.5 Billion
4. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
5. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
6. Boston Scientific Begins PLATINUM PLUS Trial for PROMUS(R) Element(TM) Stent System
7. A Year Since Obamas Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward
8. GenomeQuest Announces Boston Seminar: Sequence Data Management for Next Generation Sequencing
9. Caturano and Company to Host Boston Biotech Event, "BIBA Biotech 2010 and Beyond"
10. UMass Boston's Venture Development Center Announces New Bio-Science Partner
11. Molecular Genetics Core Facility at Childrens Hospital Boston Selects HybSelect from febit for Targeted Resequencing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Virginia (PRWEB) June 03, 2015 Photo-Eyewear™ ... changed its name to PogoTec™, Inc. ( http://www.PogoTec.com ... its electronic wearable device products and technologies it is ... creation of three business divisions, PogoTec™ will provide focused ... devices as follows: , , On-Track™ ...
(Date:6/3/2015)... GEA's Panther™ NS3006L is a ... fully-equipped laboratory unit that is designed for continuous operation ... plants. The Panther™ NS3006L achieves the same results as ... easy installation with simple operation, quick maintenance and is ... used in many different industries, such as food, dairy, ...
(Date:6/2/2015)... TORONTO , June 2, 2015 /PRNewswire/ - Aptose ... clinical-stage company developing new therapeutics that target the underlying ... and Drug Administration (FDA) has granted the company orphan ... myeloid leukemia (AML). APTO-253, a first-in-class inducer of the ... a Phase Ib clinical trial in patients with AML, ...
(Date:6/2/2015)... , June 02, 2015 Research and ... Jain PharmaBiotech,s new report "Biomarkers - Technologies, ... This report follows the broad definition of ... objectively measured and evaluated as an indicator of ... pharmacological responses to a therapeutic intervention. Tests based ...
Breaking Biology Technology:Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 3GEA Announces the Panther™ NS3006L, a Self-Contained, Fully-Equipped Laboratory Homogenizer Well Suited for Pilot Plants 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3
... Conference Call and Webcast Today at 1:00 pm ... FRANCISCO, Calif., June 30 Anesiva,Inc. (Nasdaq: ... its first,commercial product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder,intradermal ... that reduces the pain associated with peripheral,intravenous (IV) ...
... today,received information from Danske Bank, that the Danske Bank ... - through,acquisition today of 502,300 shares now owns 1,804,514 ... to 5,99% of the share capital and 5,99%,of the ... Exiqon,s corporate mission is to combine leading-edge scientific,expertise in ...
... with ADHD ages 6 to 65, RARITAN, N.J., ... and behavioral disorder treated in children(1), and,according to the ... 70 percent of children with ADHD continue to exhibit ... about eight million, or,one in 20, adults in the ...
Cached Biology Technology:Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 2Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 3Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 4Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 5FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults 2FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults 3FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults 4
(Date:5/21/2015)... The Sync Project™ , a global ... today announced a collaborative partnership with Berklee,s Institute ... on collaboration on original research, joint course development and ... collaboration, The Sync Project and BerkleeICE are exploring the ... the 2015-2016 academic year.  The course ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... a well-rounded UAS delegation representing private industry, government, and academia, ... AUVSI,s Unmanned 2015 conference last week in Atlanta ... UAS industry met with over 200 hundred people from companies ... ecosystem. "Our message is clear and consistent," ... Rich Knoll . "If you want to fly UAS, you ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... the remote highlands of eastern Suriname discovered 24 species ... with florescent purple markings and other amphibians, fish and ... the findings from a 2005 expedition led by Conservation ... in 2006 demonstrate the value of exploring unknown regions ...
... so many people continue to suffer from life-altering, chronic pain ... answer -- and an effective treatment -- has long eluded ... haven’t worked very well. , A Northwestern University ... to be an old memory trace that essentially gets stuck ...
... cauliflower While orange cauliflower may seem unappealing to ... have identified the genetic mutation behind the unusual hue. ... including maize, potato, rice, sorghum and wheat. , ... Li Li and colleagues -- and described in the ...
Cached Biology News:Researchers find 24 species believed new to science in Suriname rainforest 2Old memory traces in brain may trigger chronic pain 2Old memory traces in brain may trigger chronic pain 3Discovery in orange cauliflower may lead to more nutritious crops 2
... and antibody-based immunoaffinity matrices, such as ... times without compromising antigen-antibody reactivity, the ... agents has precluded the application of ... The CHEMICON Re-Blot Plus Western Blot ...
Applications: Western blotting ...
...
... efficiencies and the chemistry of light production ... benefit that they require simple triggering conditions ... This benefit has been exploited to great ... compounds can also be easily modified to ...
Biology Products: